Windlas Biotech Consolidated March 2022 Net Sales at Rs 122.13 crore, up 14.35% Y-o-Y
NULL13-05-2022
Earnings Call for Q4FY22 of Windlas Biotech
Conference Call with Windlas Biotech Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.13-05-2022
Windlas Biotech Ltd - 543329 - Statement Of Deviation
Statement of deviation(s) or variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 for quarter ended March 31, 202212-05-2022
Windlas Biotech Ltd - 543329 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Recording Of Conference Call
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Recording of Conference Call Audio12-05-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the quarter ended March 31, 202212-05-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation12-05-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release12-05-2022
Windlas Biotech Ltd - 543329 - Board recommends Dividend
Windlas Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12, 2022, inter alia, has recommended a Dividend of Rs. 3.50/- per Equity Share of face value of Rs. 5/- each (@70%). The said dividend,if declared by the Members of the Company at the ensuing Annual General Meeting (AGM), will be credited/despatched within three weeks of the conclusion of said AGM.12-05-2022